# Pixium Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pixium-vision

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.pixium-vision.com
- Total disclosed funding: $21M
- Latest round: Series A (Oct 28, 2013)
- Investors on record: 5

## About

Pixium Vision SA specializes in developing advanced medical technologies aimed at restoring vision in patients suffering from advanced macular degeneration. Their innovative solutions enhance visual perception using retinal implants and camera-equipped glasses.Founded in 2011 in Paris, France, Pixium Vision SA focuses on the design and development of vision restoration technologies. The company has executed four significant deals throughout its operations. CEO Lloyd Diamond has steered the company through its strategic initiatives, leading to its recent IPO in which the firm raised EUR 34.50 mn, marking the total amount raised at EUR 34.50 mn from various funding rounds.Pixium Vision SA's primary product is the PRIMA System, specifically designed to address advanced macular degeneration (AMD). This system includes a retinal implant that interacts with glasses equipped with a camera, enabling users to perceive visual information and regain some lost visual capabilities. The company targets hospitals and ophthalmology clinics across Europe, with a focus on markets in France, Germany, and Italy, striving to improve the quality of life for individuals affected by AMD.In 2022, Pixium Vision SA reported a revenue of EUR 0, with an EBITDA of EUR -14,788,349.80. Their revenue generation model primarily relies on partnerships with healthcare facilities and direct sales of the PRIMA System to medical institutions, which includes structured contracts covering support, maintenance, and staff training.Pixium Vision SA plans to leverage its recent funding to advance the development of upcoming products aimed at enhancing visual restoration technologies. The company is also exploring expansion into additional European markets, seeking to broaden its reach by the end of 2024. Recent investment from Kreos Capital will support these initiatives as they aim to improve patient access to their innovative solutions.

## Funding rounds

- Series A, Oct 28, 2013, $3.4M — Omnes Capital, Amundi
- Series A, Jun 15, 2012, $18M — Abingworth, Global Life Science Ventures, PolyTechnos Venture-Partners, Omnes Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A
- PolyTechnos Venture-Partners (https://capitalatlas.ai/funds/polytechnos-venture-partners) — Series A
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Amundi (https://capitalatlas.ai/funds/amundi) — Series A